ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 681

Identification of Treatment Naïve Patients with Psoriatic Arthritis Who Will Require a TNF Inhibitor

Dan Gromer1, Laura C. Coates2, Oliver FitzGerald3, Blanca Himes4, Philip Helliwell5 and Alexis Ogdie6, 1University of Pennsylvania, Medical Student, Philadelphia, PA, 2University of Oxford, Oxford, United Kingdom, 3Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, 4Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, 5LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, 6Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: DMARDs, Outcome measures, Psoriatic arthritis, therapy and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease that affects the skin, joints, and soft tissues. No metrics exist to indicate whether an untreated patient is unlikely to respond to oral therapies and will require therapy with a biologic.  The objective of this study was to predict TNFi prescription among treatment naïve patients initiating methotrexate. We further aimed to identify subgroups of patients at baseline that would likely need a TNFi.

Methods: Data from the Tight Control of Psoriatic Arthritis (TICOPA) trial was used. In TiCOPA, patients with at least one tender and swollen joint who were treatment naïve were randomized into one of two arms: intensive management and standard of care.  We used all available baseline data to build models to predict the need for a subsequent TNFi within the 48 week study. We first applied a standard prediction modeling approach using stepwise Cox regression models.  However, because of correlation among baseline variables (i.e., collinearity) and instability of the models, we decided to apply novel “machine learning” methods (e.g., tree-based classification, clustering methods, and latent class analysis, LCA) using R 3.4.4 with imported packages. Target categorical variables were cut from continuous variables after graphical exploration and trial analyses.

Results: Among the 188 participants who agreed to share data for additional studies, 44 initiated a TNFi during the 48-week study period.  Exploration with comparison tests, stepwise regression, and tree-based models identified the PsAQoL score and the Patient Global Assessment (PtGA) as valuable predictors of TNFi prescription. Using LCA, we were able to define a two-class model (Figure 1A) that classified patients who were more and less likely to require a TNFi.  In addition to receipt of a TNFi, these classes were defined by a CRP ≥ 25, PsAQoL ≥ 7, and TJC ≥ 10 (the most predictive and non-redundant set of variables). We termed the classes “Less Inflamed” and “More Inflamed” for simplicity. Importantly, PtGA was a strong predictor of being in one of these classes; as PtGA increased, the likelihood of being the “more inflamed” class increased. Dividing PtGA into Low (≤40), middle (40-70), and high (≥70) categories accurately predicted class membership (Figure 1B).  In summary, PtGA was single best predictor of requiring a TNFi; baseline PtGA≥70 has a HR of 2.62 (1.42-4.80) for requiring a TNFi and correctly classifies 76% of patients.

Conclusion: At baseline, participants in the TICOPA trial could be classified into two groups, “more inflamed” and “less inflamed” based on three variables and patient global was the single best predictor of class and receipt of a TNFi. The baseline patient global assessment of treatment naïve patients with PsA yields valuable prognostic information and is an important tool for clinical decision-making in this population.


Disclosure: D. Gromer, None; L. C. Coates, None; O. FitzGerald, AbbVie, Bristol-Myers Squibb, Novartis, Pfizer Inc, 2,AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, UCB, 9; B. Himes, None; P. Helliwell, AbbVie, Janssen, 2,AbbVie, Amgen, Janssen, Novartis, Pfizer Inc, ucb, 9; A. Ogdie, Pfizer, Inc.; Novartis, 2,Abbvie, Amgen, BMS, Corrona, Lilly, Novartis, Pfizer, Takeda, 5.

To cite this abstract in AMA style:

Gromer D, Coates LC, FitzGerald O, Himes B, Helliwell P, Ogdie A. Identification of Treatment Naïve Patients with Psoriatic Arthritis Who Will Require a TNF Inhibitor [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/identification-of-treatment-naive-patients-with-psoriatic-arthritis-who-will-require-a-tnf-inhibitor/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-treatment-naive-patients-with-psoriatic-arthritis-who-will-require-a-tnf-inhibitor/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology